Farxiga Class Action Lawsuit in New York

The Farxiga class action litigation alleges that AstraZeneca, the manufacturer of Farxiga (dapagliflozin), failed to adequately warn patients and physicians about serious risks, including diabetic ketoacidosis (DKA), urinary tract infections, and an increased risk of bladder cancer. Plaintiffs claim they suffered severe injuries that could have been prevented with proper warnings. If you were prescribed Farxiga and experienced these complications, you may have a claim.

Yes. New York residents who were prescribed Farxiga and suffered serious side effects such as DKA, kidney failure, necrotizing fasciitis, or bladder cancer may be eligible to file a lawsuit or join existing class action litigation. Under CPLR §214, New York’s statute of limitations for personal injury claims is generally three years from the date of injury, so acting promptly is essential to preserve your rights.

Qualifying injuries in Farxiga litigation typically include diabetic ketoacidosis (DKA), Fournier’s gangrene (necrotizing fasciitis of the genitals), urinary tract infections, kidney damage or acute kidney injury, and bladder cancer. These are serious, life-threatening conditions that the FDA has required updated warning labels to address. A New York attorney can evaluate whether your specific diagnosis and timeline support a viable claim.

New York’s statute of limitations for pharmaceutical injury claims is three years under CPLR §214, generally running from the date you discovered—or reasonably should have discovered—the connection between Farxiga and your injury. Missing this deadline bars your claim entirely. Document your diagnosis, medical records, and prescription history now and consult a New York personal injury attorney without delay.